

HR 1503

Orange Book Transparency Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 5, 2019

Current Status: Became Public Law No: 116-290.

Latest Action: Became Public Law No: 116-290. (Jan 5, 2021)

Law: 116-290 (Enacted Jan 5, 2021)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/1503>

Sponsor

Name: Rep. Kelly, Robin L. [D-IL-2]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (13 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Craig, Angie [D-MN-2]	D · MN		Apr 2, 2019
Rep. Dingell, Debbie [D-MI-12]	D · MI		Apr 2, 2019
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Apr 2, 2019
Rep. Kennedy, Joseph P., III [D-MA-4]	D · MA		Apr 2, 2019
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Apr 2, 2019
Rep. Pallone, Frank, Jr. [D-NJ-6]	D · NJ		Apr 2, 2019
Rep. Ruiz, Raul [D-CA-36]	D · CA		Apr 2, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Apr 2, 2019
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Apr 4, 2019
Rep. Van Drew, Jefferson [D-NJ-2]	D · NJ		Apr 4, 2019
Rep. Walden, Greg [R-OR-2]	R · OR		Apr 4, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Apr 12, 2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]	D · FL		May 1, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Mar 27, 2019
Health, Education, Labor, and Pensions Committee	Senate	Discharged From	Dec 7, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 19	Related bill	Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Summary (as of Jan 5, 2021)

Orange Book Transparency Act of 2020

This bill modifies requirements for the Food and Drug Administration (FDA) to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded.

The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.

Actions Timeline

- **Jan 5, 2021:** Signed by President.
- **Jan 5, 2021:** Became Public Law No: 116-290.
- **Dec 24, 2020:** Presented to President.
- **Dec 10, 2020:** Mrs. Dingell asked unanimous consent that the House agree to the Senate amendment.
- **Dec 10, 2020:** Mrs. Dingell asked unanimous consent to take the bill, H.R. 1503 from the Speaker's Table and agree to the Senate amendment. (consideration: CR H7130-7131)
- **Dec 10, 2020:** Resolving differences -- House actions: On motion that the House agree to the Senate amendment Agreed to without objection.(text: CR H7130-7131)
- **Dec 10, 2020:** On motion that the House agree to the Senate amendment Agreed to without objection. (text: CR H7130-7131)
- **Dec 10, 2020:** Motion to reconsider laid on the table Agreed to without objection.
- **Dec 8, 2020:** Message on Senate action sent to the House.
- **Dec 7, 2020:** Measure laid before Senate by unanimous consent. (consideration: CR S7244)
- **Dec 7, 2020:** Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
- **Dec 7, 2020:** Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S7242-7243)
- **Dec 7, 2020:** Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7242-7243)
- **May 9, 2019:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **May 8, 2019:** Ms. Eshoo moved to suspend the rules and pass the bill, as amended.
- **May 8, 2019:** Considered under suspension of the rules. (consideration: CR H3486-3488)
- **May 8, 2019:** DEBATE - The House proceeded with forty minutes of debate on H.R. 1503.
- **May 8, 2019:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **May 8, 2019:** Considered as unfinished business. (consideration: CR H3491)
- **May 8, 2019:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 422 - 0 (Roll no. 187).(text: CR H3486-3487)
- **May 8, 2019:** On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 422 - 0 (Roll no. 187). (text: CR H3486-3487)
- **May 8, 2019:** Motion to reconsider laid on the table Agreed to without objection.
- **May 2, 2019:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-47.
- **May 2, 2019:** Placed on the Union Calendar, Calendar No. 25.
- **Apr 3, 2019:** Committee Consideration and Mark-up Session Held.
- **Apr 3, 2019:** Ordered to be Reported (Amended) by Voice Vote.
- **Mar 27, 2019:** Subcommittee Consideration and Mark-up Session Held.
- **Mar 27, 2019:** Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
- **Mar 6, 2019:** Referred to the Subcommittee on Health.
- **Mar 5, 2019:** Introduced in House
- **Mar 5, 2019:** Referred to the House Committee on Energy and Commerce.